Pennsylvania herpes dating scruffy guys dating
WH: Numerous publications from the Halford Lab between 20 highlight that a live-attenuated HSV-2 vaccine, the active ingredient in the Theravax vaccine, is 50 to 100 times more effective than the GEN-003 subunit vaccine.Three decades of publications document the repeated failure of HSV-2 glycoprotein D-based subunit vaccines, which is the primary active ingredient in the GEN-003 vaccine.If so, will you be measuring shedding by viral titer, a decrease in transmission during times of asymptomatic shedding, or both?WH: I absolutely want to run many more trials of RVx’s vaccines to address this and many other questions about the efficacy of this live-attenuated HSV-2 vaccine.Can you comment on the difference between Theravax HSV-2 vaccine and prophylactic Valtrex in this regard? Valtrex has limited use in reducing shedding; by most accounts about a 2-fold reduction in shedding.We expect that, given the reductions in symptoms participants are reporting, that the live Theravax HSV-2 vaccine would reduce shedding by 10 to 100-fold, but until we make those measurements, that is little more than speculation.JB: The data (number of outbreaks) from the people who received the vaccination were self-reported, a notoriously unreliable method for data collection.In other words, the possibility for the blurring of real and placebo effects becomes a problem.
Human clinical trials for the live Profavax vaccine, RVx’s preventative vaccine, will take longer to complete; perhaps 2-3 years.JB: Will the upcoming data include more participants, more data on the first 20 participants, or both?WH: The further data we plan to make public over the next 12 months will come from the n=20 people who were enrolled in the 2016 Phase I clinical trial conducted in St Kitts.Still no data or peer review of their claims, but this morning, RVx issued a press release about a Phase I safety study of the company's Theravax (therapeutic) vaccine.JB: Phase I trials are usually conducted for safety only.
However, the focus for the moment is more about reducing herpes patients’ symptoms than dotting all of the i’s and t’s necessary to offer a formal scientific explanation as to why the therapeutic HSV-2 vaccine works, and measuring the magnitude of the effect.